// App-Quantinova.ai

P171 : Bimekizumab in bDMARD-naïve patients with active psoriatic arthritis: improvements in PsARC over 24 weeks in the Phase 3 BE OPTIMAL trial

Researchers

Presenter

  • Iain McInnes

Principal Investigators

  • Barbara Ink

  • Rajan Bajracharya

  • Vanessa Taieb

  • William R Tillett

Medical Centers

  • Royal National Hospital for Rheumatic Diseases, Department of Life Sciences, University of Bath, Bath, United Kingdom

  • Rheumatology, UCB Pharma, Colombes, France

  • Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Rheumatology, UCB Pharma, Slough, United Kingdom

Locations

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved